RxDoctor Payments Data

Muhammad Panhwar

Interventional Cardiology · Bemidji, MNNPI 1851742522

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $9,428 of the $14,404 with a category attached, or 65.5%. 10 manufacturers reported payments, led by Penumbra, Inc. at 31.4% of the total. Reporting peaked in 2024 at $8,262 and has fallen 97.2% since, to $231 in 2025.

$14,404in general payments, 2019–2025

Across 104 payments — averaging $138.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$5K
  • Abbott$4K
  • Medtronic$4K
  • Bard Peripheral Vascular, Inc.$984
  • Boston Scientific$672
  • Abiomed$303
  • plus $81 from 4 others

What the payments were for

  • Travel & lodging$9,42865%
  • Food & beverage$4,88734%
  • Education$891%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,404 in reported general payments places this provider in the 70th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$84,952
Medicare patients
500
Services billed
1,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$56,306
BrilintaTicagrelor19$12,248
Metoprolol Succinate206$3,608
Amiodarone Hcl17$1,433
ClopidogrelClopidogrel Bisulfate72$1,235
Isosorbide Mononitrate ErIsosorbide Mononitrate19$581
Furosemide98$543
Rosuvastatin Calcium35$397
Atorvastatin Calcium36$325
Lisinopril24$257
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$205
Nitroglycerin19$191
Carvedilol15$131
Losartan Potassium13$111
Metoprolol Tartrate12$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$29$12,24819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 84 interventional cardiology providers in Minnesota.

Other interventional cardiology in Bemidji

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →